{
    "2020-01-15": [
        [
            {
                "time": "",
                "original_text": "【天风医药】健帆生物：业绩预告回归高增长态势，激励考核提升业绩信心",
                "features": {
                    "keywords": [
                        "健帆生物",
                        "业绩预告",
                        "高增长",
                        "激励考核",
                        "业绩信心"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "健帆生物：预计2019年净利润5.23亿元至6.03亿元",
                "features": {
                    "keywords": [
                        "健帆生物",
                        "净利润",
                        "2019年",
                        "5.23亿元",
                        "6.03亿元"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "健帆生物（300529）：业绩符合预期，Q4恢复快速增长！【动态点评|西南证券医药朱国广团队】",
                "features": {
                    "keywords": [
                        "健帆生物",
                        "300529",
                        "业绩",
                        "符合预期",
                        "Q4",
                        "快速增长",
                        "西南证券",
                        "医药",
                        "朱国广团队"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}